Successful treatment of anti-PTX3 positive seronegative rheumatoid arthritis with upadacitinib.

Haojie Xu, Bang Su, Rong Li, Lu Wang, Jiaxin Zhou, Lidan Zhao

International journal of rheumatic diseases 2023 Sep 13

filter terms:

all
phenotype
show more »
show less «

Seronegative rheumatoid arthritis (SNRA) can be a rapid-progressing and highly disabling disease. Anti-PTX3 autoantibody may be a potential biomarker in SNRA diagnosis. SNRA patients could respond well to upadacitinib. © 2023 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.

Citation

Haojie Xu, Bang Su, Rong Li, Lu Wang, Jiaxin Zhou, Lidan Zhao. Successful treatment of anti-PTX3 positive seronegative rheumatoid arthritis with upadacitinib. International journal of rheumatic diseases. 2023 Sep 13

PMID: 37705400

View Full Text